Key Stats for Eli Lilly Stock
- Current Price: $1,180.16
- Target Price (Mid): ~$2,060
- Street Target: ~$1,313
- Potential Total Return: ~75%
- Annualized IRR: ~14% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Eli Lilly (LLY) closed at $1,180.16 on August 14, less than 6% below its 52-week high, and buyers arriving now face an uncomfortable question. The company just posted 48% revenue growth, raised guidance again, and on August 10 won the first regulatory approval for its oral weight-loss pill outside the United States. The good news is already loud. What is left to pay for at a price that has nearly doubled in a year?
Lilly’s injectable business is enormous and still accelerating, but it is well understood and largely reflected in the multiple. The unsettled part of the story sits with the pill, Foundayo, and the pipeline behind it. The company’s own investor relations materials frame the next phase as a global rollout, and the last two weeks gave investors their first real evidence of how that rollout behaves outside the US.
The Pill Cleared Europe Before Anyone Expected a Read on Demand
On August 10, the UK’s Medicines and Healthcare products Regulatory Agency authorized Foundayo (orforglipron), Lilly’s once-daily oral GLP-1, for weight management and type 2 diabetes. It was the first approval anywhere in Europe, and it landed about two months after Novo Nordisk’s oral Wegovy reached the same market. Shares rose more than 3% on the news before giving most of it back as the broader tape softened.
The approval matters more for what it signals than for near-term revenue. A pill that can be made at scale changes the reach of the franchise, because supply and cold-chain logistics no longer gate every new market. On the Q2 call, President of Lilly International Patrik Jonsson said the major ex-US launches come in 2027, and stressed supply will not be a constraint: “there will be no gating of launches either.” With an oral, geography stops being the bottleneck.
US President Ilya Yuffa described a launch that was slow out of the gate but inflected in late July. He said the prescriber base expanded from roughly 8,000 to 36,000 in a single quarter, that volume nearly doubled versus a month earlier, and that close to 1 in 4 new patient starts now chooses Foundayo.
See historical and forward estimates for Eli Lilly stock (It’s free!) >>>
A Black Market Is Telling What the Franchise Is Worth
On August 12, Lilly filed six lawsuits against US compounding pharmacies, medical spas, and online sellers it accused of illegally selling retatrutide, its next-generation triple-receptor drug that has not been approved by any regulator anywhere. The company said it had flagged more than 200 entities to the FDA and Department of Justice and identified over 14,000 listings marketing the compound across more than 100 countries.
The allegations are unproven, and the legal campaign is a cost rather than a catalyst. Still, a drug still in Phase 3 has already spawned a black market across 100 countries. That is demand arriving years ahead of approval, and it frames the size of the opportunity Lilly is defending. On the Q2 call, Chair and CEO Dave Ricks said the clinical data package is complete, with additional manufacturing data still being gathered ahead of a US submission planned for the first quarter of 2027, a timeline Lilly pushed back from an earlier end-of-2026 target. Ricks also flagged that the filing pathway is still contested: the biologic classification Lilly wants is “active litigation” with the FDA, a genuine unknown rather than a settled catalyst.
Where the Premium Is, and Whether It Is Deserved
Lilly trades at around 22x NTM EV/EBITDA and roughly 29x NTM earnings, per TIKR. Against peers, that is a wide gap: Merck sits near 15x NTM EV/EBITDA, Roche near 12x, and Novo Nordisk, the closest competitor, near 10x. On the surface, Lilly costs more than twice what Novo does.
Lilly grew revenue 48% last quarter, carries an LTM EBIT margin near 50%, and runs more than 40 active Phase 3 programs, while Novo’s growth has slowed. A buyer at this multiple pays for durability of growth, not a turnaround, and the ex-US pill launch is the mechanism that keeps the growth rate elevated past the point where the US injectable market matures.
See how Eli Lilly performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $1,180.16
- Target Price (Mid): ~$2,060
- Potential Total Return: ~75%
- Annualized IRR: ~14% / year
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
Using TIKR’s mid-case scenario, LLY reaches a target of around $2,060 by the end of 2030, a total return of roughly 75% over about 4.4 years, or near 14% per year. The two revenue drivers are the injectable franchise, where Mounjaro and Zepbound combined for $14.9 billion in the quarter, and the ex-US oral expansion, where Foundayo sits under review in more than 40 markets with a global rollout targeted for 2027. The margin driver is operating leverage: gross margin already runs above 86%, and further mix improvement toward higher-margin incretins supports a net income margin holding in the mid-40s. The primary risk is US pricing, where realized Zepbound and Mounjaro prices declined, and management expects further erosion as commercial access broadens.
The upside case is that oral demand outside the US mirrors the domestic inflection and retatrutide clears its filing path, extending the growth curve well past 2027. The downside case is that pricing pressure compounds faster than volume offsets it, and the multiple contracts against a slower growth rate.
Conclusion
The next real test is the third-quarter report on October 29. Watch the Foundayo prescription trajectory: management pointed to a late-July inflection and 1-in-4 new-start share, so a Q3 print showing US scripts still climbing while the first UK volumes register would confirm the pill can travel. Flat or decelerating scripts, paired with sharper US price erosion, would hand the pricing bears their case and pressure the premium. For a buyer near highs, October is when the global expansion thesis stops being a promise and starts being a number.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Eli Lilly?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Eli Lilly, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Eli Lilly alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Eli Lilly on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
